Afatinib dimaleate (also known as BIBW2992MA2) is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potentially irreversible inhibiting EGFR and HER2 kinase activity. It is a salt of Afatinib( BIBW 2992), an aminocrotonylamino-substituted quinazoline derivative used for treating cancer and diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder.
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
 D.Li, et al, Oncogene., 2008, 27(34), pp 4702-4711.
 F.A.L.M. Eskens, et al, Br. J. Cancer, 2008, 98(1), pp 80-85.
 X.K.Wang, et al, Cancer Res., 2014, 74(16), pp 4431-4435.
 S.Wind, et al, Clin. Pharmacokinet., 2017, 56(3), pp 235-250.